COMP <GO>
CME vs BRK-B // ALTMAN Z-SCORE & DEBT/EQUITY
CME Group Inc. (NASDAQ) VS. Berkshire Hathaway Inc. (NYSE) • 15-METRIC TALLY: CME 8
— BRK-B 6
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: BRK-B
LAST: $303.14 (+2.27%) • MKT CAP: $106.10B
balance-sheet
0.55
LAST: $542.49 (+0.10%) • MKT CAP: $1.16T
balance-sheet
2.85
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CME VS. BRK-B)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CME | BRK-B | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.50% | 11.47% | -7.97 | BRK-B | /roic <GO> |
| EV/EBITDA & P/E Valuation | 40.2x | 9.7x | +30.52 | BRK-B | /valuation <GO> |
| Free Cash Flow Yield | 3.95% | 2.09% | +1.86 | CME | /fcf-yield <GO> |
| Operating Margin | 64.90% | 27.80% | +37.10 | CME | /operating-margins <GO> |
| Net Profit Margin | 62.50% | 22.30% | +40.20 | CME | /net-margins <GO> |
| Revenue Growth (YoY) | 6.40% | 3.93% | +2.47 | CME | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 3.71% | 0.00% | +3.71 | CME | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 0.55 | 2.85 | -2.30 | BRK-B | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 4/9 | +4.00 | CME | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 3.55% | +3.35 | BRK-B | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 65.4 | 66.8 | -1.42 | BRK-B | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 0.61 | +0.40 | CME | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.3x | 24.3x | -0.04 | CME | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $106.10B | $1.16T | -$1.05T | BRK-B | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CME REV | BRK-B REV | CME GROSS % | BRK-B GROSS % | CME FCF | BRK-B FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.52B | $371.44B | 44.0% | — | $4.19B | $25.04B |
| FY 2024 | $6.13B | $371.43B | 44.0% | — | $3.60B | $11.62B |
| FY 2023 | $5.58B | $364.48B | 44.0% | — | $3.20B | $29.79B |
| FY 2022 | — | $302.02B | — | — | — | $21.89B |
| FY 2021 | — | $276.19B | — | — | — | $26.15B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CME // BETA 1.01
BRK-B // BETA 0.61